Last week in GLP1 (2025/09/22)
Here’s what happened last week in the GLP1 ecosystem:
📊 Study: Wegovy pill shows 16.6% weight loss
📑 GLP1s could reduce all-cause mortality by up to 6% by 2045
Read more
🗞️ Looking to keep up with GLP1s? We've moved to Substack
GLP1.Guide is now best viewed on Substack: Read the rest on Substack New information is posted there first, and in the future this site will be converted to redirect directly to Substack. Thanks for supporting GLP1.guide, we'll see you over on Substack!
Oral GLP1s you've probably never heard of
Most people have heard of Mounjaro, Zepbound, Wegovy, Ozempic and Rybelsus by now. The words “VK2735” or “Orforglipron” mean nothing to most people, though now almost everyone is familiar with GLP1s as a class of drugs (at the very least the effects). There are some obscure GLP1s under development that
Last week in GLP1 (2025/10/13)
We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 🔎 GLP1 interfering with medical imaging? 💚 More research on GLP1’s benefits for stopping substance & alcohol Abuse 📑 Ketones + GLP1s prevent muscle loss (in mice) 🚨 Semaglutide Withdrawal and it’s effects on Type
Last week in GLP1 (2025/10/06)
We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 💼 Costco is now selling heavily discounted GLP1s 🦘 Buzz in Australia around GLP1s as a public benefit 💊 Excitement is growing around oral GLP1s 🏫 Harvard doctor doubles down on benefits of GLP1 for inflammation